Lifecore Biomedical (LFCR) agreed to be acquired by Webster Equity Partners for $6.28 per share in cash plus contingent value rights, valuing the deal up to $663.7 million. The cash consideration represents a 49.5% premium to the last closing price. Stock resumed trading and surged 58% to $6.62.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
